Fusion Protein Caspase Activation via TEV Cleavage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies, including chemotherapy and targeted therapies, face challenges in selectively inducing apoptosis in cancer cells while minimizing harm to normal cells, and they often require long recovery periods for the immune system.
Innovation Solution
A fusion protein containing an inactive form of caspase 3, 7, 8, or 10, combined with tobacco etch virus protease (TEV), is used to specifically activate these caspases in tumor cells, inducing apoptosis through a recognition site uniquely cleaved by TEV.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemotherapy is used to kill tumor cells, then cell division is interrupted and tumor cells die, but normal cells are also damaged causing side effects
Solution Approach 1:
The patent applies local quality by creating a fusion protein that is specifically expressed in tumor cells through tumor-specific promoters, ensuring that the caspase-activating enzyme is only active where needed. This localized expression mechanism allows selective induction of apoptosis in tumor cells while sparing normal cells, directly resolving the contradiction between tumor cell killing efficiency and harm to normal cells.
Solution Approach 2:
The patent uses an intermediary approach by employing a fusion protein as a mediator that carries both the caspase enzyme and a tumor-specific promoter. This intermediary fusion protein acts as a targeted delivery system that activates caspases only in tumor cells, thereby mediating selective cell death without directly damaging normal cells.
2Reliability
If targeted therapy with monoclonal antibodies is used, then cancer cells are specifically recognized and bound, but the immune system bears an extraordinary burden requiring long pauses between treatments
Solution Approach 1:
The patent applies self-service by using tumor-specific promoters that are constitutively active in tumor cells, allowing the fusion protein to be continuously expressed without external intervention. This self-regulating mechanism eliminates the need for periodic immune system recovery periods, as the therapy acts continuously at the cellular level without requiring systemic immune activation.
Solution Approach 2:
The patent substitutes the mechanical immune system-based targeted therapy with a direct molecular mechanism using fusion proteins that carry caspase enzymes. This replacement eliminates the need for immune system-mediated targeting and subsequent recovery periods, achieving continuous action through direct cellular manipulation.
3Adaptability or versatility
If gene therapy approaches are used to introduce nucleic acids into cells, then treatment potential is improved, but the complexity of delivery mechanisms increases
Solution Approach 1:
The patent applies merging by combining the tumor-specific promoter and caspase-activating enzyme into a single fusion protein entity. This consolidation simplifies the delivery mechanism compared to separate gene therapy components, as the fusion protein can be delivered as a single unit that simultaneously provides tumor specificity and apoptotic activity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for efficient and specific induction of apoptosis in tumor cells, overcoming resistance mechanisms and minimizing damage to normal cells, with the potential for reduced immune system burden.
Implementation Method 1
TEV recognizes the recognition sites (recognition sequences) ENLYFQS or ENLYFQG in an inactive form of altered caspase 3 and/or caspase 7 and/or caspase 8 and/or caspase 10
Data Source
AI summary
The invention relates to a fusion protein containing a selective cell death-inducing enzyme system for use in the therapy and/or treatment of cancer and tumors in humans and animals, a process, and its use.